Common use of Notification and Meeting Clause in Contracts

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.3.1 or 3.3.3, then CombinatoRx shall notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within fifteen (15) days after such written notice to discuss in good faith for a period of not more than fifteen (15) days CombinatoRx's concerns and Fovea's development activities with respect to the Collaboration Combination.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.3.1 3.3.1, 3.3.2, 3.3.3 or 3.3.33.3.5, then CombinatoRx shall notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within fifteen (15) days after such written notice to discuss in good faith for a period of not more than fifteen (15) days CombinatoRx's concerns and Fovea's development activities with respect to the Collaboration CombinationCombinations.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.3.1 Section 4.5.1 or 3.3.34.5.2, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within fifteen thirty (1530) days after such written notice to discuss in good faith for a period of not more than fifteen twenty-one (1521) days CombinatoRx's concerns and Fovea's development activities plans with respect to the Collaboration CombinationLicensed Combinations.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.3.1 3.9.1, 3.9.2 or 3.3.33.9.3, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within fifteen thirty (1530) days after such written notice to discuss in good faith for a period of not more than fifteen twenty-one (1521) days CombinatoRx's concerns and Fovea's development activities plans with respect to the Collaboration CombinationCombinations.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations to use Commercially Reasonable Efforts to achieve the milestones described under Sections 3.3.1 Section 4.1.1 or 3.3.34.1.3, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within fifteen (15) days after such written notice to discuss in good faith for a period of not more than fifteen seven (157) days CombinatoRx's ’s concerns and Fovea's ’s development activities with respect to the Collaboration CombinationLicensed Combinations.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.3.1 Section 4.1.1, 4.1.2 or 3.3.34.1.5, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within fifteen (15) days after such written notice to discuss in good faith for a period of not more than fifteen seven (157) days CombinatoRx's ’s concerns and Fovea's ’s development or commercialization activities with respect to the Collaboration CombinationLicensed Combinations.